Tech Company Financing Transactions
ILiAD Biotechnologies Funding Round
ILiAD Biotechnologies, operating out of New York, secured $42.8 million from Knott Partners and private investors.
Transaction Overview
Company Name
Announced On
9/6/2022
Transaction Type
Venture Equity
Amount
$42,800,000
Round
Series D
Investors
Knott Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to conduct a Phase 2b Human Challenge study to determine if vaccination with BPZE1 prevents colonization from wild-type Bordetella pertussis infection.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
230 East 15th St. 1-A
New York, NY 10003
USA
New York, NY 10003
USA
Phone
Website
Email Address
Overview
ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate is BPZE1, a live attenuated pertussis vaccine that is currently in Phase 2 and has successfully completed two Phase 1 human clinical trials.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Keith Rubin
Chief Financial Officer
Walter Greenblatt
Chief Operating Officer
Ken Solovay
Controller
James Ramadei
General Manager
Marcel Thalen
Vice President
Stanley Kim
Browse more venture capital transactions:
Prev: 9/6/2022: Gig and Take venture capital transaction
Next: 9/6/2022: Credix Finance venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs